147 related articles for article (PubMed ID: 26687385)
21. Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?
Randall TC; Armstrong K
Curr Treat Options Oncol; 2016 Aug; 17(8):39. PubMed ID: 27315065
[TBL] [Abstract][Full Text] [Related]
22. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
23. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
24. Increased Risk of Hereditary Prostate Cancer in Italian Families with Hereditary Breast and Ovarian Cancer Syndrome Harboring Mutations in
D'Elia G; Caliendo G; Tzioni MM; Albanese L; Passariello L; Molinari AM; Vietri MT
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292577
[TBL] [Abstract][Full Text] [Related]
25. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
Schubert EL; Mefford HC; Dann JL; Argonza RH; Hull J; King MC
Genet Test; 1997; 1(1):41-6. PubMed ID: 10464624
[TBL] [Abstract][Full Text] [Related]
26. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
[TBL] [Abstract][Full Text] [Related]
27. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
[TBL] [Abstract][Full Text] [Related]
28. Yield of targeted genotyping for the recurring pathogenic variants in cancer susceptibility genes in a healthy, multiethnic Israeli population.
Bernstein-Molho R; Galmor L; Laitman Y; Segev S; Friedman E
Cancer; 2021 Oct; 127(19):3599-3604. PubMed ID: 34157778
[TBL] [Abstract][Full Text] [Related]
29. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
[TBL] [Abstract][Full Text] [Related]
30. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of genetic alterations in hereditary cancer susceptibility genes in the Ashkenazi Jewish women community of Mexico.
Díaz-Velásquez CE; Gitler R; Antoniano A; Kershenovich Sefchovich R; De La Cruz-Montoya AH; Martínez-Gregorio H; Rojas-Jiménez EA; Cortez Cardoso Penha R; Terrazas LI; Wegman-Ostrosky T; Levi-Lahad E; Zabaleta J; Perdomo S; Vaca-Paniagua F
Front Genet; 2023; 14():1094260. PubMed ID: 36845387
[No Abstract] [Full Text] [Related]
32. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.
De Leeneer K; Van Bockstal M; De Brouwer S; Swietek N; Schietecatte P; Sabbaghian N; Van den Ende J; Willocx S; Storm K; Blaumeiser B; Van Asperen CJ; Wijnen JT; Leunen K; Legius E; Michils G; Matthijs G; Blok MJ; Gomez-Garcia E; De Paepe A; Tischkowitz M; Poppe B; Claes K
Breast Cancer Res Treat; 2012 May; 133(1):393-8. PubMed ID: 22370629
[TBL] [Abstract][Full Text] [Related]
34. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Roa BB; Boyd AA; Volcik K; Richards CS
Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
[TBL] [Abstract][Full Text] [Related]
35. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
[TBL] [Abstract][Full Text] [Related]
36. Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel.
Kwong A; Shin VY; Au CH; Law FB; Ho DN; Ip BK; Wong AT; Lau SS; To RM; Choy G; Ford JM; Ma ES; Chan TL
J Mol Diagn; 2016 Jul; 18(4):580-94. PubMed ID: 27157322
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
Fostira F; Tsitlaidou M; Papadimitriou C; Pertesi M; Timotheadou E; Stavropoulou AV; Glentis S; Bournakis E; Bobos M; Pectasides D; Papakostas P; Pentheroudakis G; Gogas H; Skarlos P; Samantas E; Bafaloukos D; Kosmidis PA; Koutras A; Yannoukakos D; Konstantopoulou I; Fountzilas G
Breast Cancer Res Treat; 2012 Jul; 134(1):353-62. PubMed ID: 22434525
[TBL] [Abstract][Full Text] [Related]
38. Genetic analyses of male breast cancer in Israel.
Sverdlov RS; Barshack I; Bar Sade RB; Baruch RG; Hirsh-Yehezkel G; Dagan E; Feinmesser M; Figer A; Friedman E
Genet Test; 2000; 4(3):313-7. PubMed ID: 11142766
[TBL] [Abstract][Full Text] [Related]
39. The I1307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds.
Petrukhin L; Dangel J; Vanderveer L; Costalas J; Bellacosa A; Grana G; Daly M; Godwin AK
Cancer Res; 1997 Dec; 57(24):5480-4. PubMed ID: 9407954
[TBL] [Abstract][Full Text] [Related]
40. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
